| Literature DB >> 25280459 |
Xiaoxiao Chen, Qicai Chen, Lili Chen, Pengpeng Zhang, Juan Xiao, Shumei Wang1.
Abstract
BACKGROUND: Metabolic Syndrome (MS) is increasingly becoming a major worldwide clinical and public health issue. Thus it is extremely important to study the history of MS and search for the most likely component contributing to start the cascade of confusions of MS.Entities:
Mesh:
Year: 2014 PMID: 25280459 PMCID: PMC4209018 DOI: 10.1186/1471-2458-14-1033
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1A 7-state Markov model to describe the progression of metabolic components.
General information of the study cohort
| Variables a | Baseline (N=7510) | 1-year follow-up (N=6480) | 2-year follow-up (N=5420) | 3-year follow-up (N=4644) | 4-year follow-up (N=2899) | 5-year follow-up (N=1106) |
|
|---|---|---|---|---|---|---|---|
| Age (years) | 41.02±10.26 | 41.86±10.21 | 43.57±10.16 | 45.38±10.16 | 47.67±10.86 | 46.53±7.72 | <0.0001 |
| Sex (male) | 5118 (68.17%) | 4299 (66.34%) | 3592 (66.27%) | 3041 (65.48%) | 1879 (64.82%) | 811 (73.33%) | <0.0001 |
| Overweight or obesity | 3088 (41.12%) | 2642 (40.77%) | 2346 (43.28%) | 2057 (44.29%) | 1198 (41.32%) | 557 (50.36%) | <0.0001 |
| Hypertension | 2237 (29.79%) | 2505 (38.66%) | 2335 (43.08%) | 2251 (48.47%) | 1568 (54.09%) | 672 (60.76%) | <0.0001 |
| Dyslipidemia | 2008 (26.74%) | 1887 (29.12%) | 1673 (30.87%) | 1447 (31.16%) | 954 (32.91%) | 362 (32.73%) | <0.0001 |
| Hyperglycemia | 614 (8.18%) | 729 (11.26%) | 770 (14.21%) | 772 (16.62%) | 615 (21.21%) | 237 (21.43%) | <0.0001 |
| MS | 893 (11.89%) | 990 (15.28%) | 985 (18.17%) | 940 (20.24%) | 661 (22.80%) | 289 (26.13%) | <0.0001 |
aValues for continuous characteristics were expressed as mean ± SD; values for categorical data were expressed as n (%).
bP for each row testing the null hypothesis that values for six years were equal.
Annual transition probabilities (%) in Markov chain models for men in the 18–40 year group
| Starting state | State after transition | ||||||
|---|---|---|---|---|---|---|---|
| No component | Isolated overweight or obesity | Isolated hypertension | Isolated dyslipidemia | Isolated hyperglycemia | 2 components | MS | |
| No component | 72.07 | 9.48 | 4.55 | 7.68 | 0.58 | 4.55 | 1.09 |
| Isolated overweight or obesity | 13.51 | 52.25 | 1.03 | 3.35 | 0.51 | 24.07 | 5.28 |
| Isolated hypertension | 0 | 0 | 61.21 | 0 | 0 | 26.67 | 12.12 |
| Isolated dyslipidemia | 23.21 | 3.27 | 1.79 | 42.86 | 0.30 | 22.32 | 6.25 |
| Isolated hyperglycemia | 0 | 0 | 0 | 0 | 48.57 | 31.43 | 20.00 |
| 2 components | 3.33 | 9.07 | 9.44 | 2.50 | 0.83 | 54.17 | 20.65 |
| MS | 0 | 0 | 3.78 | 0 | 0 | 23.92 | 72.30 |
Annual transition probabilities (%) in Markov chain models for women in the 18–40 year group
| Starting state | State after transition | ||||||
|---|---|---|---|---|---|---|---|
| No component | Isolated overweight or obesity | Isolated hypertension | Isolated dyslipidemia | Isolated hyperglycemia | 2 components | MS | |
| No component | 86.38 | 3.71 | 2.15 | 3.76 | 0.80 | 2.30 | 0.90 |
| Isolated overweight or obesity | 37.81 | 44.27 | 0.50 | 4.98 | 0.50 | 9.45 | 2.49 |
| Isolated hypertension | 0 | 0 | 83.82 | 0 | 0 | 13.24 | 2.94 |
| Isolated dyslipidemia | 47.57 | 5.83 | 2.91 | 25.24 | 0.97 | 10.68 | 6.80 |
| Isolated hyperglycemia | 0 | 0 | 0 | 0 | 88.64 | 9.09 | 2.27 |
| 2 components | 7.69 | 6.51 | 20.71 | 2.37 | 3.55 | 46.74 | 12.43 |
| MS | 0 | 0 | 25.00 | 0 | 0 | 42.31 | 32.69 |
Annual transition probabilities (%) in Markov chain models for men in the 40–49 year group
| Starting state | State after transition | ||||||
|---|---|---|---|---|---|---|---|
| No component | Isolated overweight or obesity | Isolated hypertension | Isolated dyslipidemia | Isolated hyperglycemia | 2 components | MS | |
| No component | 68.15 | 8.30 | 4.26 | 10.54 | 1.57 | 5.72 | 1.46 |
| Isolated overweight or obesity | 13.17 | 52.23 | 0 | 3.13 | 0.22 | 25.45 | 5.80 |
| Isolated hypertension | 0 | 0 | 64.71 | 0 | 0 | 27.01 | 8.29 |
| Isolated dyslipidemia | 24.82 | 4.61 | 3.19 | 37.59 | 1.06 | 23.05 | 5.67 |
| Isolated hyperglycemia | 0 | 0 | 0 | 0 | 56.90 | 31.03 | 12.07 |
| 2 components | 1.28 | 4.81 | 8.49 | 3.13 | 1.44 | 57.69 | 23.16 |
| MS | 0 | 0 | 2.60 | 0 | 0.21 | 22.56 | 74.64 |
Annual transition probabilities (%) in Markov chain models for women in the 40–49 year group
| Starting state | State after transition | ||||||
|---|---|---|---|---|---|---|---|
| No component | Isolated overweight or obesity | Isolated hypertension | Isolated dyslipidemia | Isolated hyperglycemia | 2 components | MS | |
| No component | 82.05 | 5.45 | 3.70 | 4.61 | 0.84 | 2.65 | 0.70 |
| Isolated overweight or obesity | 27.50 | 54.16 | 1.25 | 4.17 | 0.42 | 11.25 | 1.25 |
| Isolated hypertension | 0 | 0 | 86.80 | 0 | 0 | 11.46 | 1.74 |
| Isolated dyslipidemia | 38.25 | 3.48 | 3.48 | 42.61 | 0 | 9.57 | 2.61 |
| Isolated hyperglycemia | 0 | 0 | 0 | 0 | 73.81 | 19.05 | 7.14 |
| 2 components | 3.16 | 3.95 | 21.34 | 3.16 | 3.95 | 49.02 | 15.42 |
| MS | 0 | 0 | 4.88 | 0 | 2.44 | 36.59 | 56.09 |
Annual transition probabilities (%) in Markov chain models for men in the 50–59 year group
| Starting state | State after transition | ||||||
|---|---|---|---|---|---|---|---|
| No component | Isolated overweight or obesity | Isolated hypertension | Isolated dyslipidemia | Isolated hyperglycemia | 2 components | MS | |
| No component | 62.71 | 9.90 | 5.94 | 7.92 | 3.96 | 7.59 | 1.98 |
| Isolated overweight or obesity | 18.62 | 46.28 | 2.66 | 4.79 | 0.53 | 20.21 | 6.91 |
| Isolated hypertension | 0 | 0 | 66.40 | 0 | 0 | 29.25 | 4.35 |
| Isolated dyslipidemia | 22.97 | 1.35 | 1.35 | 36.49 | 2.70 | 29.73 | 5.41 |
| Isolated hyperglycemia | 0 | 0 | 0 | 0 | 53.57 | 30.36 | 16.07 |
| 2 components | 0.53 | 2.79 | 7.85 | 1.60 | 1.33 | 60.24 | 25.66 |
| MS | 0 | 0 | 2.13 | 0 | 0.15 | 21.46 | 76.26 |
Figure 2The predictive development of MS according to various starting components in men in the 18–40 year group.
Figure 3The predictive development of MS according to various starting components in women in the 18–40 year group.